BioWorld

June 18, 2010

OncoMed Has 'Wnt' in its Sails; Bayer Deal Adds $40M Up Front

For a firm that has yet to reach Phase II with a lead program, OncoMed Pharmaceuticals Inc. has managed some pretty impressive feats in the past few years. (BioWorld Today) Read More

Neurocrine in $235M Deal with Boehringer for GPR119 Agonists

Arginetix, Immune Control Merge Two Corridors in Vascular Space

Aquinox Raises $25M for Blood, Immune Disorders Molecule

EULAR Roundup

Stimuvax Hold Lifted in NSCLC; Oncothyreon, EMD Move Ahead

Stock Movers

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...

FB-7033 demonstrates efficacy in MASH management

BioWorld Science

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...

Illustration of antibody carrying radioactive isotope

Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

BioWorld Science

At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...